1[2]Solary E, Wity B, Caillot D, et al. Combination of quienie as apotential reversing agaent with mitoxantrone and cytoarabine forthe treatment of acute leukemia[J]. Blood, 1996,88:1198
2[3]Feldman EF, Alberts DS, Arlin Z , et al. Phase Ⅰ clinical andpharmacokinetic evaluation of high-dose mitoxantrone in comination with cytoarabine in patient with acute leukemia[J]. J ClinOncology, 1993,11: 2002
3[4]Bezwoda WR, Bermasconi C , Hutchinson RM, et al. Mitoxantrone for refractory and relapsed acute leukemia[J]. Cancer,1990,66:418
3Michieli M, Damiani D, Ermacora A, etal. P - glycoprotein,lung resistance - related protein and multidrug resistance associated protein in denovo acute non -lymphocytic leukaemia: biological and clinical implication [ J ]. Br J Heamatol, 1999,104:328 - 335.
4Stanisic S,Kalaycio M. Treatment of refractory and relapsed acute myelogenous leukemia[ J ]. Expert Rev Anticancer Ther, 2002,2 : 287-295.
5Bezwoda WR, Bermasconi C, Hutchinson RM, et al. Mitoxantrone for refractory and relapsed acute leukemia[ J ]. Cancer, 1990,66: 418.
6Peter JR,Cathryn R,David RH ,et al. A phase II study of high dose Ara-c and mitoxantrone for the treatment of relapse or refractory adult acute lymphoblasic leukemia[J]. Leuk Res,2000,24:183-187.
7Je HL, Seong JC, Jung HL,et al. Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia [ J ]. Leukemia Res, 2006,30:204 - 210.
